Cerulean Pharma, which is developing targeted therapies for kidney, ovarian and other cancers, raised $60 million by offering 8.5 million shares at $7, well below the $11 to $13 range. The company had originally planned to offer 5.0 million shares. Cerulean...read more
Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for kidney and ovarian cancer, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $60 million by offering 5.0 million shares at a price range of $11...read more
Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for kidney and ovarian cancer, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2005, plans...read more
Cerulean Pharma prices IPO at $7, well below the $11 to $13 range
Cerulean Pharma, which is developing targeted therapies for kidney, ovarian and other cancers, raised $60 million by offering 8.5 million shares at $7, well below the $11 to $13 range. The company had originally planned to offer 5.0 million shares. Cerulean...read more
16 US IPOs planned for the week of Apr 7
The following IPOs are expected to price this week: Adamas Pharmaceuticals (ADMS), which is developing treatments for CNS disorders such as Parkinson's and Alzheimer's, ...read more
Cancer biotech Cerulean Pharma sets terms for $60 million IPO
Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for kidney and ovarian cancer, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $60 million by offering 5.0 million shares at a price range of $11...read more
Cancer biotech Cerulean files for a $75 million IPO
Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for kidney and ovarian cancer, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2005, plans...read more